On ECHEMI
Home > Drugs > Changzhou Watson Pharmaceuticals Co., Ltd.
Changzhou Watson Pharmaceuticals Co., Ltd.
  • Founded in:

    1996-03-25
  • Country:

    China China
  • Address:

    No. 98, Hehai Road, Xinbei District, Changzhou
  • Tax NO.:

    91320411608126453T
  • Registered Funds:

    $18 million
  • Website:

  • Email:

Related Drugs
Trazodone Hydrochloride
Name Description Content CAS NO. Registered Holders
Trazodone hydrochloride

Extract from the above information

More

Extract from the above information

25332-39-2 46
Trazodone Hydrochloride Tablets
Trazodone hydrochloride.
Name Description Content CAS NO. Registered Holders
Trazodone hydrochloride

It is a specific 5-hydroxytryptamine reuptake inhibitor. Due to its alpha 1 adrenergic antagonism and antihistamine effects, it can induce postural hypotension. It is not a monoamine oxidase inhibitor, and unlike amphetamines, it has no excitatory effect on the central nervous system.

More

It is a specific 5-hydroxytryptamine reuptake inhibitor. Due to its alpha 1 adrenergic antagonism and antihistamine effects, it can induce postural hypotension. It is not a monoamine oxidase inhibitor, and unlike amphetamines, it has no excitatory effect on the central nervous system.

25332-39-2 46
Zaleplon Capsules
Zaleplon.
Name Description Content CAS NO. Registered Holders
Zaleplon

Extract from the above information

More

Extract from the above information

0
Zaleplon Tablets
Zaleplon.
Name Description Content CAS NO. Registered Holders
Zaleplon

Extract from the above information

More

Extract from the above information

0
Risedronate Sodium Tablets
Risedronate
Name Description Content CAS NO. Registered Holders
Sodium risedronate

It can bind to hydroxyapatite in bones and inhibit bone resorption. At the cellular level, this product inhibits osteoclasts. It reduces the absorption of bone turnover and bone remodeling, inhibits osteoclasts in osteoporosis model rats and miniature pigs, increases bone mass and bone biomechanical strength, and the increase in bone density is dose-related.

More

It can bind to hydroxyapatite in bones and inhibit bone resorption. At the cellular level, this product inhibits osteoclasts. It reduces the absorption of bone turnover and bone remodeling, inhibits osteoclasts in osteoporosis model rats and miniature pigs, increases bone mass and bone biomechanical strength, and the increase in bone density is dose-related.

115436-72-1 13
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.